After COVID-19 testing sales pushed the company’s quarterly income to over $1.3 billion last year, Hologic is beginning to spend some of that cash—albeit conservatively. The company kicked off 2021 ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® SARS-CoV-2 assay, which initially received Emergency Use Authorization (EUA) from the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback